We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to Know
Read MoreHide Full Article
In the latest trading session, Novo Nordisk (NVO - Free Report) closed at $38.26, marking a +1.95% move from the previous day. This change outpaced the S&P 500's 0.22% loss on the day. Elsewhere, the Dow saw a downswing of 0.66%, while the tech-heavy Nasdaq depreciated by 0.22%.
Heading into today, shares of the drugmaker had lost 16.9% over the past month, lagging the Medical sector's loss of 4.73% and the S&P 500's gain of 1.4%.
Analysts and investors alike will be keeping a close eye on the performance of Novo Nordisk in its upcoming earnings disclosure. The company is expected to report EPS of $0.8, down 21.57% from the prior-year quarter. In the meantime, our current consensus estimate forecasts the revenue to be $11.41 billion, indicating a 2.79% decline compared to the corresponding quarter of the prior year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $3.53 per share and a revenue of $46.1 billion, indicating changes of -10.86% and -1.46%, respectively, from the former year.
Investors might also notice recent changes to analyst estimates for Novo Nordisk. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 2.41% higher. As of now, Novo Nordisk holds a Zacks Rank of #3 (Hold).
Digging into valuation, Novo Nordisk currently has a Forward P/E ratio of 10.62. This indicates a discount in contrast to its industry's Forward P/E of 15.82.
Also, we should mention that NVO has a PEG ratio of 1.23. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.86 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 107, which puts it in the top 44% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to Know
In the latest trading session, Novo Nordisk (NVO - Free Report) closed at $38.26, marking a +1.95% move from the previous day. This change outpaced the S&P 500's 0.22% loss on the day. Elsewhere, the Dow saw a downswing of 0.66%, while the tech-heavy Nasdaq depreciated by 0.22%.
Heading into today, shares of the drugmaker had lost 16.9% over the past month, lagging the Medical sector's loss of 4.73% and the S&P 500's gain of 1.4%.
Analysts and investors alike will be keeping a close eye on the performance of Novo Nordisk in its upcoming earnings disclosure. The company is expected to report EPS of $0.8, down 21.57% from the prior-year quarter. In the meantime, our current consensus estimate forecasts the revenue to be $11.41 billion, indicating a 2.79% decline compared to the corresponding quarter of the prior year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $3.53 per share and a revenue of $46.1 billion, indicating changes of -10.86% and -1.46%, respectively, from the former year.
Investors might also notice recent changes to analyst estimates for Novo Nordisk. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 2.41% higher. As of now, Novo Nordisk holds a Zacks Rank of #3 (Hold).
Digging into valuation, Novo Nordisk currently has a Forward P/E ratio of 10.62. This indicates a discount in contrast to its industry's Forward P/E of 15.82.
Also, we should mention that NVO has a PEG ratio of 1.23. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.86 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 107, which puts it in the top 44% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.